Principe et al. demonstrated that TGFβ is of equal importance in this kind of treatment, as KC mouse (P48-Cre × LSL-KRASG12D) receiving wild-type CD8+ T cell still displayed disease progression, but tumor growth was ceased when the CD8+ T cells harvested from Tgfbr1+/− mice were injected [134]. The gene discussed is CD8A; the disease is neoplasm.